OCT Clinical Trials   Report issue

For profit Phase 2 Phase 3
Founded: Saint Petersburg Russian Federation (2005)

Organization Overview

First Clinical Trial
2016
NCT03036163
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

OCT Clinical Trials | OCT LLC | OCT Rus, LLC

Active Ingredients

Drugs in Phase 3 Trials (4)

adalimumab (humira) (1 trial)

levofloxacin (levaquin) (1 trial)

nemonoxacin (1 trial)

olokizumab (4 trials)

Drugs in Phase 2 Trials (3)

isoniazid (nydrazid) (1 trial)

pbtz169 (2 trials)

pf-114 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Necrosis (Phase 3)

Pneumonia (Phase 3)

Pneumonia, Bacterial (Phase 3)

Tuberculosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 7